|
|
News Breaks | | | | December 13, 2012 | | 16:25 EDT |  | AZN, ZAGG, CLWR, RIGL, BBY, SAM, S | On The Fly: Closing Wrap
Stocks on Wall Street finished lower but off their worst levels amid more political gamesmanship over the fiscal cliff. Both House Speaker John Boehner and Senate Majority Leader Harry Reid made comments regarding the increasing gridlock in negotiations, sending the averages lower just before midday. The averages touched their lows around 2:00 pm, but rallied in the last half hour of trading after reports that the President would meet with Speaker Boehner this evening for further cliff talks... ECONOMIC EVENTS: In the U.S., weekly jobless claims fell 29,000 to 343,000, versus expectations for a drop to 369,000. Producer prices in the month of November fell 0.8%, versus an expected decline of 0.5%. "Core" prices, excluding food and energy, rose 0.1%, which matched expectations. Retail sales rose 0.3% in November, which missed expectations for an increase of 0.5%. In Europe, the region's finance ministers approved the release of more financial aid to Greece and came to terms on a foundation for ECB oversight of a true banking union... COMPANY NEWS: Shares of Clearwire (CLWR) rose 41c, or 14.91%, to $3.16 after Sprint (S) disclosed an offer to buy the remaining stake in the company it does not already own for $2.90 per share. Clearwire said that its talks with Sprint are ongoing. Meanwhile, Sprint shares slipped fractionally, down 2c, or 0.35%, to $5.64... MAJOR MOVERS: Among the notable gainers was Best Buy (BBY), up $1.94, or 15.93%, to $14.12 after the Star Tribune said the company's founder Richard Schulz will soon make an offer for the company. Also higher were ZAGG (ZAGG), up 73c, or 10.27%, to $7.84 after the company announced a $10M share repurchase program, and Boston Beer (SAM), up $17.71, or 15.50%, to $131.94 after raising its FY12 EPS guidance. Among the noteworthy losers was Rigel Pharmaceuticals (RIGL), which fell $2.94, or 34.88%, to $5.49 after an RA drug it is developing in partnership with AstraZeneca (AZN) failed to meet one of its endpoints in a trial. Shares of AstraZeneca also traded down $1.44, or 2.94%, to $47.46... INDICES: The Dow was down 74.73, or 0.56%, to 13,170.72; the Nasdaq was down 21.65, or 0.72%, to 2,992.16; and the S&P 500 was 9.03, or 0.63%, to 1,419.45. | |
|
News For CLWR;S;BBY;ZAGG;SAM;RIGL;AZN From The Last 14 Days Check below for free stories on CLWR;S;BBY;ZAGG;SAM;RIGL;AZN the last two weeks. |
|
|
| May 21, 2013 | | 13:43 EDT |  | S, CLWR | Clearwire reschedules special shareholder meeting
 Subscribe for More Information | | | 13:36 EDT |  | S, CLWR | Clearwire holder Crest Financial protest company's delay of vote on merger
Crest Financial Limited, the largest of the independent minority stockholders of Clearwire Corporation (CLWR), protested the decision of the Clearwire Board of Directors to adjourn the Clearwire special meeting to consider Sprint's (S) increased offer price of $3.40 per share. Crest said that it has sent a letter to the Clearwire Board of Directors urging them to resist Sprint's new offer so that Clearwire can pursue direct offers through a competitive process once the bidding war over Sprint is concluded. Crest's letter to the Clearwire Board said, "Sprint's new offer for Clearwire still significantly undervalues Clearwire and its assets and provides no protections to minority stockholders." | | | 12:36 EDT | | BBY | On The Fly: Midday Wrap
Subscribe for More Information | | | 12:32 EDT |  | BBY | Options with decreasing implied volatility: PXP ARNA BBY OPK CSC
| | | 12:11 EDT |  | CLWR | Follow-up: Clearwire upgraded to Market Perform from Sell at Janco
Subscribe for More Information | | | 12:08 EDT | | CLWR | Clearwire upgraded to Market Perform from Sell at Janco
| | | 10:24 EDT |  | CLWR | Sprint, Clearwire deal likely gets done, says Wells Fargo
Wells Fargo believes Sprint's (S) raised offer for Clearwire (CLWR) is likely enough to get the deal approved by shareholders. Wells has an Outperform rating on Sprint and Market Perform rating on Clearwire. | | | 10:20 EDT |  | BBY | Best Buy down over 3% in volatile trading, levels to watch
Subscribe for More Information | | | 09:48 EDT | | CLWR | Clearwire resumes trading, up 3.7% to $3.38
Subscribe for More Information | | | 09:32 EDT | | S, CLWR | Clearwire to resume trading at 9:45 am ET
Subscribe for More Information | | | | 09:29 EDT | | AZN | AstraZeneca says Phase III studies of Naloxegol met primary, secondary endpoints
AstraZeneca (AZN) presented the results of two pivotal Phase III studies of naloxegol showing the 25 mg dose of the investigational drug met its primary and secondary endpoints for efficacy and showed a safety profile consistent with previous studies. Data was presented at the Digestive Disease Week meeting in Orlando, Florida. The primary endpoint in both trials was percentage of OIC responders, versus placebo, over 12 weeks of treatment. The secondary endpoints included the 12-week response rate in a laxative inadequate response population, the median time to first spontaneous bowel movement and the number of days per-week with at least one bowel movement. Plans for naloxegol will be finalized over the coming months, incorporating the outcome of ongoing discussions with health authorities in the US, EU and Canada, the company said. Naloxegol, a peripherally-acting mu-opioid receptor antagonist, has been specifically designed for the treatment of opioid-induced constipation and is part of the exclusive worldwide license agreement announced on 21 September 2009, between AstraZeneca and Nektar Therapeutics (NKTR). | | | 09:25 EDT | | BBY | On The Fly: Pre-market Movers
Subscribe for More Information | | | 09:23 EDT | | CLWR, S | Clearwire receives increase offer from Sprint
Clearwire (CLWR) confirmed that it has received a revised offer from Sprint (S) to acquire the approximately 50% stake in the company it does not currently own for $3.40 per share. Consistent with its fiduciary duties and in consultation with its financial and legal advisors, the Special Committee of the Clearwire board will review this revised proposal from Sprint. | | | 09:22 EDT | | CLWR, S | Clearwire receives increase offer from Sprint
Subscribe for More Information | | | 09:03 EDT | | S, CLWR | Sprint increases offer for Clearwire to $3.40 per share from $2.97
Subscribe for More Information | | | 09:01 EDT | | S, CLWR | Sprint increases offer for Clearwire to $3.40 per share
Subscribe for More Information | | | 08:57 EDT | | CLWR, S | Sprint to raise bid for Clearwire above $2.97 prior offer, DJ says
Subscribe for More Information | | | 08:55 EDT | | CLWR | Clearwire trading halted, pending news
Subscribe for More Information | | | 07:09 EDT | | BBY | Best Buy expects investment in price competitiveness to continue into Q2
Subscribe for More Information | | | 07:07 EDT | | BBY | Best Buy reports Q1 SSS fell 1.3%
Subscribe for More Information | | |
|
|
|
|
|
|
